Amai Proteins

Sweet Designer Proteins as a Sugar Substitute

Agriculture & Food Technologies
Private

Company Overview

Snapshot

Founded in December 2016 by Ilan Samish, Amai Proteins operates with 51–200 employees. The company has raised a total of $22.82 million across 12 funding rounds and has attracted 11 investors. In February 2026, the company's flagship sweet protein, Sweelin®, received FDA GRAS approval, paving the way for accelerated commercialization in the U.S. market.

Business overview

Amai Proteins develops designer proteins as a sugar substitute for the food and beverage industry. Its core product, Sweelin®, is a hyper-sweet protein derived from the serendipity berry, designed to reduce added sugar in products by 40-70% without compromising taste, health, cost, or sustainability. The company utilizes its Pro-Cube platform, which integrates AI-driven computational protein design, microbial precision fermentation for scalable production, and food technology for product assessment. Amai Proteins serves the food and beverage sectors, focusing on novel ingredients and nutrition within the broader agriculture and food technologies market.

Strategic signal

Amai Proteins is poised for significant market expansion following recent regulatory approvals for its sweet protein, Sweelin®. In May 2026, Sweelin® received approval from the Singapore Food Agency, expanding the company's regulatory footprint into Asia. This follows the U.S. FDA's GRAS approval in February 2026, which clears the path for accelerated commercialization in the American market. These approvals signal strong validation of the company's technology and its potential to disrupt the sugar substitute market globally, offering investors a clear path to increased market penetration and revenue growth.

Company Intelligence Q&A

What is Amai Proteins' flagship product?
Amai Proteins' flagship product is Sweelin®, a calorie-free sweet protein designed to reduce added sugar in food and beverages by 40-70%.
When did Sweelin® receive FDA GRAS approval?
Sweelin® received U.S. FDA GRAS (Generally Recognized as Safe) approval in February 2026, clearing the path for accelerated commercialization in the U.S. market.
Has Sweelin® received regulatory approval in other regions?
Yes, in May 2026, Sweelin® received approval from the Singapore Food Agency, expanding Amai Proteins' regulatory footprint into Asia.
What was a key partnership for Amai Proteins in 2020?
In December 2020, Ocean Spray and Amai Proteins partnered to create the first protein-sweetened, reduced-sugar cranberry juice.
Which investors participated in an A Round in April 2020?
In April 2020, Amai Proteins received an A Round from investors including iAngels.

External links